Macular edema
Conditions
Interventions
Macular edema - corticosteroid group:NA
macular edema - anti-VEGF agents:NA
Fundus neovascularization- corticosteroid group:NA
Fundus neovascularization - anti-VEGF group:NA
Sponsors
Second Xiangya Hospital of CSU
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosed with macular edema or neovascular diseases of the fundus; 2. Patients with macular edema must meet the following criteria: OCT shows CST >= 250µm, and there is vision decline related to macular edema; CST is defined as the circular area with a diameter of 1 millimeter centered on the fovea centralis, and its thickness is provided in quantifiable values on the OCT software. 3. No opacity of refractive media or pupil constriction that affects fundus examination. 4. Intravitreous drug injection was proposed. 5. Age > 18 years old; 6. Have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Existing ophthalmic diseases that cause visual changes due to other reasons (such as retinal detachment, macular hole, retinal traction in the macular area, premacular membrane, etc.); 2. Uncontrolled glaucoma (defined as intraocular pressure = 25 mmHg despite anti-glaucoma medication treatment), or severe glaucoma causing a cup-to-disc ratio > 0.8, or a history of glaucoma filtration surgery; 3. Active intraocular or periocular infection or intraocular inflammation at the time of screening (e.g., infectious blepharitis, infectious conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis, etc.); 4. Received retinal photocoagulation treatment within 3 months prior to screening; 5. A history of vitrectomy; 6. A history of vitreous hemorrhage within 2 months prior to screening; 7. A history of ophthalmic surgery involving the macular area; 8. Aphakia (excluding pseudophakia) or posterior lens capsule defect (excluding YAG laser posterior capsulotomy after intraocular lens implantation); 9. Any of the following systemic conditions: severe endocrine, cardiovascular, hematological, liver, kidney, or other systemic diseases, as well as individuals with low immune function or any uncontrollable clinical issues (such as HIV/AIDS, malignancy, active hepatitis, severe mental, neurological, cardiovascular, respiratory, or other systemic diseases).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| central subfield thickness;optical coherence tomography photo; | — |
Secondary
| Measure | Time frame |
|---|---|
| Best Corrected Visual Acuity;eye pressure;slit-lamp examination;optical coherence tomography angiography;color fundus photography;Fundus fluorescence angiography; | — |
Countries
China
Contacts
Public ContactLuo Jing
Second Xiangya Hospital of CSU
Outcome results
None listed